Us Drug Hemophilia a and B Recombinant Factor Replacement Therapy Market Growth, Size, Share and Forecast to 2024

Submitted by: Submitted by

Views: 10

Words: 534

Pages: 3

Category: Business and Industry

Date Submitted: 07/21/2016 10:59 PM

Report This Essay

Summary

Congenital Hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.

The US is the largest global hemophilia market, due to high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. This market growth will be driven by increasing rates of prevalent cases of hemophilia A and B, and increasing uses of recombinant replacement factors in hemophilia A and B patients over the forecast period.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Browse full report with TOC@ https://marketreportscenter.com/reports/329528/hemophilia-a-and-b-recombinant-factor-replacement-therapy-us-drug-forecast-and-market-analysis-to-2024

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market.

Reasons to buy

- Understand and...